Results 201 to 210 of about 1,605,786 (390)
Radiation-before-pathology approach in the palliative oncology setting: a pragmatic clinical trial protocol (RT-NOW). [PDF]
Young S+9 more
europepmc +1 more source
H2O2‐Generating Advanced Nanomaterials for Cancer Treatment
H2O2‐generating nanoplatforms can exploit tumor redox imbalance for O2 and toxic reactive oxygen species generation, leading to hypoxia reversal, and apoptosis of cancer cells, respectively. This review highlights the mechanisms of these nanoplatforms, including exogenous H₂O₂ delivery, endogenous amplification, and metal peroxides, which leads to ...
Kiyan Musaie+8 more
wiley +1 more source
Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan” [PDF]
Chung-Feng Huang+5 more
doaj +1 more source
Incidence and Predictors of Complications Following Percutaneous Liver Biopsy: A Large Italian Multicentre Study. [PDF]
Colapietro F+24 more
europepmc +1 more source
A bioengineered skin equivalent composed of electrospun poly(ε‐caprolactone) (PCL) and the bioactive peptide Fmoc‐FRGD is developed for severe burn treatment. This scaffold promotes full‐thickness skin regeneration by supporting cellular adhesion and integration. In‐vitro and in‐vivo studies show enhanced mechanical stability, accelerated wound closure,
Dana Cohen‐Gerassi+11 more
wiley +1 more source
Bacillary Hemoglobinuria: Induction by Liver Biopsy in Naturally and Experimentally Infected Animals [PDF]
H. J. Olander+2 more
openalex +1 more source
Minimal residual disease (MRD) leads to cancer relapse and poor survival in ovarian cancer. The lack of representative 3D models limits therapy development. The microfluidics‐based high throughput 3D microtumor platform described here generates clinically‐relevant MRD models. The 3D microtumors recapitulate the molecular signatures of MRD from patients.
Xingyun Yang+14 more
wiley +1 more source